CD8A and neoplasm: Preclinical investigation suggested that sotorasib might induce an inflammatory tumor microenvironment, increasing infiltration of CD8+ T cells (Canon et al., 2019), which could be a contributing factor to the occurrence of immune-related hepatotoxicity following combination or sequential use of sotorasib with immune checkpoint inhibitors.